Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Quit smoking, nicotine free: Oriola to distribute Acetium® lozenge in Finland

Posted on: 12 Mar 18

Biohit Oyj, Press release, March 12, 2018 at 10:30 am local time (EET)

Biohit Oyj and Oriola Oy have signed an agreement for the distribution of the smoking cessation product, Acetium lozenge in Pharmacies and other Oriola sales channels in Finland. Launch date for the product will be announced later.

The new Acetium lozenge is an effective and safe product that helps quit smoking without nicotine or any of the potential side-effects of medicinal intervention methods. Acetium lozenge is used during smoking and it eliminates cigarette smoke-derived carcinogenic acetaldehyde in the saliva. According to the clinical trial, Acetium lozenge helps to quit smoking (1-3).

Sales Director Minna Tähtinen, Oriola Oy: ” It's great that our cooperation with Biohit expands to cover the distribution of Acetium lozenge. We want to offer a comprehensive range of products to our pharmacy customers so they can help consumers with their different needs. Pharmacies have an important role in smoking cessation, as they offer products as well as expert advice to support smoking cessation.”

CEO Semi Korpela, Biohit Oyj: "Acetium lozenge is a breakthrough in developing nicotine-free smoking cessation methods. Acetium lozenge enables the release of tobacco without side effects and the nicotine dependence or the withdrawal symptoms arising from immediate termination.”

Additional information: 
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861

Myyntijohtaja Minna Tähtinen
puh. +358 46 876 5215,

1. Syrjänen K, Eronen K, Hendolin P, Paloheimo L, Eklund C, Bäckström A, Suovaniemi O. Slow-release L-cysteine (Acetium®) lozenge is an effective new method in smoking cessation. A randomized, double-blind, placebo-controlled intervention. Anticancer Res 2017;37:3639-3648.



Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group.

Oriola in brief

Oriola Oyj provides the widest service offering to healthcare operators in Finland and Sweden. We have knowledge of the market from producer to consumer. We will help you succeed and serve your customers better. Oriola is a Finnish stock-listed company in Nasdaq Helsinki. Company has 2 600 employees and net sales of 1,5 billion in 2017.


Last updated on: 12/03/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.